SIRT1 activation rescues doxorubicin-induced loss of functional competence of human cardiac progenitor cells

International Journal of Cardiology

Volumn 189, Issue 1, 2015, Pages 30-44

  De Angelis, Antonella ^a   Piegari, Elena ^a   Cappetta, Donato ^a   Russo, Rosa ^a   Esposito, Grazia ^a   Ciuffreda, Loreta Pia ^a   Ferraiolo, Fiorella Angelica Valeria ^a   Frati, Caterina ^b   Fagnoni, Francesco ^c   Berrino, Liberato ^a   Quaini, Federico ^b   Rossi, Francesco ^a   Urbanek, Konrad ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Doxorubicin induced cardiomyopathy; Human cardiac progenitor cells; Resveratrol; SIRT1

Indexed keywords

DOXORUBICIN; PROTEIN KINASE B; PROTEIN P53; RESVERATROL; SIRTUIN 1; SOMATOMEDIN C; SIRT1 PROTEIN, RAT; STILBENE DERIVATIVE;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC STEM CELL; CARDIOMYOPATHY; CELL AGING; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HEART FAILURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ACETYLATION; RAT; SENESCENCE; SIGNAL TRANSDUCTION; ANALYSIS OF VARIANCE; ANIMAL; APOPTOSIS; CARDIAC MUSCLE CELL; CARDIOMYOPATHIES; CELL CULTURE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; FISCHER 344 RAT; IMMUNOHISTOCHEMISTRY; METABOLISM; NONPARAMETRIC TEST; NORMAL DISTRIBUTION; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; STEM CELL; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARDIOMYOPATHIES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MYOCYTES, CARDIAC; NORMAL DISTRIBUTION; RANDOM ALLOCATION; RATS; RATS, INBRED F344; SIRTUIN 1; STATISTICS, NONPARAMETRIC; STEM CELLS; STILBENES;

EID: 84929162587     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.438     Document Type: Article

References (79)

1. T.M. Suter, M.S. Ewer, Cancer drugs and the heart: importance and management, Eur. Heart J. 34 (2013) 1102-1111.
2. T. Eschenhagen, T. Force, M.S. Ewer, et al, CV side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology, Eur. J. Heart Fail. 13 (2011) 1-10.
3. S.E. Lipshultz, S.R. Lipsitz, S.E. Sallan, et al, Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia, J. Clin. Oncol. 23 (2005) 2629-2636.
4. P.K. Singal, N. Iliskovic, Doxorubicin-induced cardiomyopathy, N. Engl. J. Med. 339 (1998) 900-905.
5. E. Piegari, A. De Angelis, D. Cappetta, et al, Doxorubicin induces senescence and impairs function of human cardiac progenitor cells, Basic Res. Cardiol. 108 (2013) 334.
6. C. Huang, X. Zhang, J.M. Ramil, et al, Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice, Circulation 121 (2010) 675-683.
7. L. Prezioso, S. Tanzi, F. Galaverna, et al, Cancer treatment-induced cardiotoxicity: a cardiac stem cell disease? Cardiovasc. Hematol. Agents Med. Chem. 8 (2010) 55-75.
8. A. De Angelis, E. Piegari, D. Cappetta, et al, Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function, Circulation 121 (2010) 276-292.
9. R. Bolli, A.R. Chugh, D. D'Amario, et al, Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial, Lancet 378 (2011) 1847-1857.
10. K. Malliaras, R.R. Makkar, R.R. Smith, et al, Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction), J. Am. Coll. Cardiol. 63 (2014) 110-122.
11. D. D'Amario, C. Fiorini, P.M. Campbell, et al, Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathies, Circ. Res. 108 (2011) 857-861.
12. D. Cesselli, A.P. Beltrami, F. D'Aurizio, et al, Effects of age and heart failure on human cardiac stem cell function, Am. J. Pathol. 179 (2011) 349-366.
13. R.R. Smith, L. Barile, H.C. Cho, et al, Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens, Circulation 115 (2007) 896-908.
14. B.J. Morris, Seven sirtuins for seven deadly diseases of aging, Free Radic. Biol. Med. 56 (2013) 133-171.
15. M.C. Haigis, D.A. Sinclair, Mammalian sirtuins: biological insights and disease relevance, Annu. Rev. Pathol. 5 (2010) 253-295.
16. L. Guarente, Sir2 links chromatin silencing, metabolism, and aging, Genes Dev. 14 (2000) 1021-1026.
17. L.B. Boyette, R.S. Tuan, Adult stem cells and diseases of aging, J. Clin. Med. 3 (2014) 88-134.
18. T.M. Lu, J.Y. Tsai, Y.C. Chen, et al, Downregulation of SIRT1 as aging change in advanced heart failure, J. Biomed. Sci. 21 (2014) 57.
19. M. Tanno, A. Kuno, Y. Horio, T. Miura, Emerging beneficial roles of sirtuins in heart failure, Basic Res. Cardiol. 107 (2012) 273.
20. N.R. Sundaresan, V.B. Pillai, M.P. Gupta, Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy, J. Mol. Cell. Cardiol. 51 (2011) 614-618.
21. T.K. Sin, B.T. Tam, B.Y. Yung, et al, Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis, J. Physiol. (2015) http://dx.doi.org/10.1113/jphysiol.2014.270101 (Epub ahead of print).
22. C. Zhang, Y. Feng, S. Qu, et al, Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53, Cardiovasc. Res. 90 (2011) 538-545.
23. M. Tanno, A. Kuno, T. Yano, et al, Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure, J. Biol. Chem. 285 (2010) 8375-8382.
24. E.D. Danz, J. Skramsted, N. Henry, J.A. Bennett, R.S. Keller, Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the SIRT1 pathway, Free Radic. Biol. Med. 46 (2009) 1589-1597.
25. C. Bearzi, M. Rota, T. Hosoda, et al, Human cardiac stem cells, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 14068-14073.
26. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, L. Gianni, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev. 56 (2004) 185-229.
27. L. Gianni, L. Viganò, A. Locatelli, et al, Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer, J. Clin. Oncol. 15 (1997) 1906-1915.
28. T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods 65 (1983) 55-63.
29. G.P. Dimri, X. Lee, G. Basile, et al, A biomarker that identifies senescent human cells in culture and in aging skin in vivo, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9363-9367.
30. C. Riccardi, I. Nicoletti, Analysis of apoptosis by propidium iodide staining and flow cytometry, Nat. Protoc. 1 (2006) 1458-1461.
31. P. Anversa, G. Olivetti, Cellular basis of physiological and pathological myocardial growth, In: E. Page, H.A. Fozzard, R.J. Solaro (Eds.), Handbook of Physiology, Oxford Univ Press, New York 2002, pp. 75-144.
32. F. Quaini, K. Urbanek, A.P. Beltrami, et al, Chimerism of the transplanted heart, N. Engl. J. Med. 346 (2002) 5-15.
33. + cardiac stem cells from the adult mouse and rat heart, Nat. Protoc. 9 (2014) 1662-1681.
34. A.P. Beltrami, L. Barlucchi, D. Torella, et al, Adult cardiac stem cells are multipotent and support myocardial regeneration, Cell 114 (2003) 763-776.
35. Z.C. Ding, X. Lu, M. Yu, et al, Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis, Cancer Res. 74 (2014) 3441-3453.
36. H.G. Hui-Chou, J.B. Olenczak, C.B. Drachenberg, S.M. Shea, E.D. Rodriguez, Short-term application of doxorubicin chemotherapy immunosuppressive side effects for composite tissue allotransplantation, Ann. Plast Surg. 68 (2012) 215-221.
37. X.Y. Zhang, W.G. Li, Y.J. Wu, M.T. Gao, Amelioration of doxorubicin-induced myocardial oxidative stress and immunosuppression by grape seed proanthocyanidins in tumour-bearing mice, J. Pharm Pharmacol. 57 (2005) 1043-1052.
38. C. Ferraro, L. Quemeneur, A.F. Prigent, C. Taverne, J.P. Revillard, N. Bonnefoy-Berard, Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells, Cancer Res. 60 (2000) 1901-1907.
39. MA Khan, H.C. Chen, X.X. Wan, et al, Regulatory effects of resveratrol on antioxidant enzymes: a mechanism of growth inhibition and apoptosis induction in cancer cells, Mol. Cells 35 (2013) 219-225.
40. L Peltz, J. Gomez, F. Marquez Alencastro, et al, Resveratrol exerts dosage and duration dependent effect on human mesenchymal stem cell development, PLoS One 7 (2012) e37162.
41. E.J. Calabrese, M.P. Mattson, V. Calabrese, Dose response biology: the case of resveratrol, Hum. Exp. Toxicol. 29 (2010) 1034-1037.
42. F. Ades, D. Zardavas, A.C. Pinto, C. Criscitiello, P. Aftimos, E. de Azambuja, Cardiotoxicity of systemic agents used in breast cancer, Breast 23 (2014) 317-328.
43. S. Bielack, D. Carrle, P.G. Casali, ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up, Ann. Oncol. 20 (2009) 137-139.
44. N. Nasrin, V.K. Kaushik, E. Fortier, et al, JNK1 phosphorylates SIRT1 and promotes its enzymatic activity, PLoS One 4 (2009) e8414
45. M. Tanno, J. Sakamoto, T. Miura, K. Shimamoto, Y. Horio, Nucleocytoplasmic shuttling of the NAD +-dependent histone deacetylase SIRT1, J. Biol. Chem. 282 (2007) 6823-6832.
46. T. Sasaki, B. Maier, K.D. Koclega, et al, Phosphorylation regulates SIRT1 function, PLoS One 3 (2008) e4020.
47. S.A. Beausoleil, M. Jedrychowski, D. Schwartz, et al, Large-scale characterization of HeLa cell nuclear phosphoproteins, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 12130-12135.
48. R.R. Alcendor, S. Gao, P. Zhai, et al, SIRT1 regulates aging and resistance to oxidative stress in the heart, Circ Res. 100 (2007) 1512-1521.
49. R. Frazzi, R. Valli, I. Tamagnini, B. Casali, N. Latruffe, F. Merli, Resveratrol-mediated apoptosis of Hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation, Int J. Cancer 132 (2013) 1013-1021.
50. B. Peck, C.Y. Chen, K.K. Ho, et al, SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2, Mol. Cancer Ther. 9 (2010) 844-855.
51. J. Luo, A.Y. Nikolaev, S. Imai, et al, Negative control of p53 by Sir2a promotes cell survival under stress, Cell 107 (2001) 137-148.
52. H. Vaziri, S.K. Dessain, E. Ng Eaton, et al, hSIR2 (SIRT1) functions as an NAD-dependentp53 deacetylase, Cell 107 (2001) 149-159.
53. J. Smith, Human Sir2 and the 'silencing' of p53 activity, Trends Cell Biol. 12 (2002) 404-406.
54. Y. Wang, X. Zhao, D. Shi, et al, Overexpression of SIRT1 promotes high glucose-attenuated corneal epithelial wound healing via p53 regulation of the IGFBP3/IGF-1R/AKT pathway, Invest. Ophthalmol. Vis. Sci. 54 (2013) 3806-3814.
55. Z. Feng, W. Hu, E. de Stanchina, et al, The regulation of AMPKbeta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways, Cancer Res. 67 (2007) 3043-3053.
56. AJ. Levine, W. Hu, Z. Feng, The P53 pathway: what questions remain to be explored? Cell Death Differ. 13 (2006) 1027-1036.
57. K. Urbanek, M. Rota, S. Cascapera, et al, Cardiac stem cells possess growth factorreceptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival, Circ. Res. 97 (2005) 663-673.
58. D. Torella, M. Rota, D. Nurzynska, et al, Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression, Circ. Res. 94 (2004) 514-524.
59. S.Y. Jang, S.Y. Kim, Y.S. Bae, p53 deacetylation by SIRT1 decreases during protein kinase CKII downregulation-mediated cellular senescence, FEBS Lett. 585 (2011) 3360-3366.
60. M. Di Trapani, G. Bassi, M. Ricciardi, et al, Comparative study of immune regulatory properties of stem cells derived from different tissues, Stem Cells Dev. 22 (2013) 2990-3002.
61. M.H. Arafa, N.S. Mohammad, H.H. Atteia, H.R. Abd-Elaziz, Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats, J. Physiol. Biochem. 70 (2014) 701-711.
62. A.M. Osman, S.E. Al-Harthi, O.M. AlArabi, et al, Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin-treated animals, Cancer Cell Int. 13 (2013) 52.
63. J. Dudka, R. Gieroba, A. Korga, et al, Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity, Evid. Based Complement. Alternat. Med. 2012 (2012) 606183.
64. L.C. Magnano, N. Martínez Cibrian, X. Andrade González, X. Bosch, Cardiac complications of chemotherapy: role of prevention, Curr. Treat. Options Cardiovasc. Med. 16 (2014) 312.
65. D.J. Rossi, C.H. Jamieson, I.L. Weissman, Stems cells and the pathways to aging and cancer, Cell 132 (2008) 681-696.
66. N.E. Sharpless, R.A. DePinho, How stem cells age and why this makes us grow old, Nat. Rev. Mol. Cell Biol. 8 (2007) 703-713.
67. L. Guarente, H. Franklin, Epstein lecture: sirtuins, aging and medicine, N. Engl. J. Med. 364 (2011) 2235-2244.
68. A. Carrizzo, M. Forte, A. Damato, et al, Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases, Food Chem. Toxicol. 61 (2013) 215-226.
69. H. Li, N. Xia, U. Förstermann, Cardiovascular effects and molecular targets of resveratrol, Nitric Oxide 26 (2012) 102110.
70. D.A. Sinclair, L. Guarente, Small-molecule allosteric activators of sirtuins, Annu. Rev. Pharmacol. Toxicol. 54 (2014) 363-380.
71. D. D'Amario, M.C. Cabral-Da-Silva, H. Zheng, et al., Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration, Circ. Res. 108 (2011) 1467-1481.
72. L. Liu, T.A. Rando, Manifestations and mechanisms of stem cell aging, J. Cell Biol. 193 (2011) 257-266.
73. J. Campisi, F. d'Adda di Fagagna, Cellular senescence: when bad things happen to good cells, Nat. Rev. Mol. Cell Biol. 8 (2007) 729-740.
74. C.M. Beauséjour, A. Krtolica, F. Galimi, et al., Reversal of human cellular senescence: roles of the p53 and p16 pathways, EMBO J. 22 (2003) 4212-4222.
75. H.F. Yuan, C. Zhai, X.L. Yan, et al, SIRT1 is required for long-term growth of human mesenchymal stem cells, J. Mol. Med. 90 (2012) 389-400.
76. Y. Li, T.O. Tollefsbol, p16(INK4a) suppression by glucose restriction contributes to human cellular lifespan extension through SIRT1-mediated epigenetic and genetic mechanisms, PLoS One 6 (2011) e17421.
77. S. Wang, P. Song, M.H. Zou, Inhibition of AMP-activated protein kinase alpha (AMPKalpha) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1, J. Biol. Chem. 287 (2012) 8001-8012.
78. W. Zheng, Y.B. Lu, S.T. Liang, et al, SIRT1 mediates the protective function of Nkx2.5 during stress in cardiomyocytes, Basic Res. Cardiol. 108 (2013) 364.
79. J. Tomé-Carneiro, M. Larrosa, A. González-Sarrías, F.A. Tomás-Barberán, M.T. García-Conesa, J.C. Espín, Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence, Curr. Pharm. Des. 19 (2013) 6064-6093.